X0303 4 2009-07-16 0 0001339455 Somaxon Pharmaceuticals, Inc. SOMX 0001024004 HALE DAVID F C/O SOMAXON PHARMACEUTICALS 3830 VALLEY CENTRE DRIVE, SUITE 705-461 SAN DIEGO CA 92130 1 0 0 0 Stock options (right to buy) 1.17 2009-07-16 4 A 0 50000 A 2019-07-15 Common Stock 50000 50000 I By Hale Family Trust UTD 2/10/86 Fifty percent of these stock options will vest upon approval by the U.S. Food and Drug Administration of the Company's New Drug Application for its product candidate Silenor(R) (doxepin), and the remaining 50% will vest upon the Company's consummation of a strategic collaboration relating to Silenor that is approved by the Board of Directors, subject to Reporting Person's continued service to the Company through each such vesting date. Not applicable to this transaction. /s/ Matthew Onaitis, Attorney-in-fact 2009-07-20